株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

髄芽腫 : パイプライン分析

Medulloblastoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229773
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
髄芽腫 : パイプライン分析 Medulloblastoma - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 95 Pages
概要

髄芽腫は子供に最もよく見られる悪性の脳腫瘍で、定義上、小脳に発生します。症状としては、朝頭痛がするものの、時間が経つにつれて改善されます。また、無気力や吐き気、歩行困難、バランスが取れないといったことも起きます。髄芽腫は中枢神経系の他の部位にも広がることがあります。治療としては、化学療法、手術、生物療法、放射線治療などがあります。

当レポートでは、髄芽腫の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、休止中のプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

髄芽腫 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明な製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Bayer AG
  • DelMar Pharmaceuticals, Inc.
  • Ignyta, Inc.
  • Lipocure Ltd.
  • MacroGenics, Inc.
  • Medicenna Therapeutics, Inc.
  • MEI Pharma, Inc.
  • Novartis AG
  • Novogen Limited
  • Progenics Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • 武田薬品工業

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8827IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H2 2016, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 3 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Medulloblastoma Overview
  • Therapeutics Development
  • Pipeline Products for Medulloblastoma - Overview
    • Pipeline Products for Medulloblastoma - Comparative Analysis
    • Medulloblastoma - Therapeutics under Development by Companies
    • Medulloblastoma - Therapeutics under Investigation by Universities/Institutes
  • Medulloblastoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Medulloblastoma - Products under Development by Companies
  • Medulloblastoma - Products under Investigation by Universities/Institutes
  • Medulloblastoma - Companies Involved in Therapeutics Development
    • Bayer AG
    • DelMar Pharmaceuticals Inc
    • Ignyta Inc
    • IMPACT Therapeutics Inc
    • Lipocure Ltd
    • MacroGenics Inc
    • NewLink Genetics Corp
    • Novogen Ltd
    • Progenics Pharmaceuticals Inc
    • Stemline Therapeutics Inc
    • ThromboGenics NV
    • VBI Vaccines Inc
    • Vyriad Inc
  • Medulloblastoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (topotecan hydrochloride + vincristine sulfate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Edotreotide Labeled Yttrium 90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-5471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • indoximod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nifurtimox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nifurtimox SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Virus to Target CD46 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pyrvinium pamoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taladegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THR-317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Trilexium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBI-1901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vimo-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMY-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Medulloblastoma - Dormant Projects
  • Medulloblastoma - Product Development Milestones
    • Featured News & Press Releases
      • Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
      • Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
      • Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
      • Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
      • Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
      • Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083
      • Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
      • Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Medulloblastoma, H2 2016
  • Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Medulloblastoma - Pipeline by Bayer AG, H2 2016
  • Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
  • Medulloblastoma - Pipeline by Ignyta Inc, H2 2016
  • Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2016
  • Medulloblastoma - Pipeline by Lipocure Ltd, H2 2016
  • Medulloblastoma - Pipeline by MacroGenics Inc, H2 2016
  • Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2016
  • Medulloblastoma - Pipeline by Novogen Ltd, H2 2016
  • Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016
  • Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2016
  • Medulloblastoma - Pipeline by ThromboGenics NV, H2 2016
  • Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2016
  • Medulloblastoma - Pipeline by Vyriad Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Medulloblastoma - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Medulloblastoma, H2 2016
  • Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top